AXSM stock analysis and price target

**Axsome Therapeutics Inc (AXSM) is poised for a bullish outlook**, as evidenced by technical indicators, analyst ratings, and pipeline advancements.

1. **Technical Indicators**:
- AXSM's closing price on August 1, 2025, was $103.02, with resistance at $114.66 and support at $99.38.
- The stock is currently below its 20-day, 10-day, and 5-day moving averages of $106.83, $103.09, and $101.29, indicating a potential upward trend.
- The MACD is -1.51, RSI is 46.55, and KDJ is 22.65, suggesting the stock is neither overbought nor oversold and indicating a neutral to bullish momentum.

|code|Ticker|Name|Date|Support Level|Resistance Level|market_code|
|---|---|---|---|---|---|---|
|AXSM|AXSM.O|Axsome Therapeutics|20250801|99.3764|114.6642|185|

|code|Ticker|Name|Date|Closing Price|market_code|
|---|---|---|---|---|---|
|AXSM|AXSM.O|Axsome Therapeutics|20250801|103.02|185|

|code|Ticker|Name|Date|Moving Average|market_code|
|---|---|---|---|---|---|
|AXSM|AXSM.O|Axsome Therapeutics|20250801|101.2920|185|

|code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code|
|---|---|---|---|---|---|---|---|---|
|AXSM|AXSM.O|Axsome Therapeutics|20250801|106.8265|46.5532|22.6483|-1.5092|185|

2. **Analyst Ratings and Price Targets**:
- The consensus rating for AXSM is "Buy" with an average 1-year price target of $175.33, suggesting a potential upside of 72.94%.
- Mizuho has reiterated an "Outperform" rating with a price target of $180.00, highlighting the company's growth potential.
- Cantor Fitzgerald has also reiterated an "Overweight" rating with a price target of $153.00, recognizing the value of AXSM's pipeline.
3. **Pipeline and Product Portfolio**:
- AXSM has a strong pipeline, with multiple products targeting CNS disorders, including Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness.
- The company's R&D Day showcased its CNS-focused pipeline strategy and upcoming catalysts, further supporting the positive outlook.
4. **Fundamental Analysis**:
- AXSM has a negative net fund flow of $5.98 million, with a block order net fund flow of $-6.95 million, indicating investor interest and potential confidence in the company's future prospects.

|code|Ticker|Name|Date|Net Fund Flow|Net Fund Flow (Block Order)|market_code|
|---|---|---|---|---|---|---|
|AXSM|AXSM.O|Axsome Therapeutics|20250106|1755676.1874|1648784.9337|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250107|-3755243.4801|-3558487.0174|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250108|862873.1143|1022311.7581|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250110|3599517.5314|3891973.5086|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250113|-1589487.9816|-1582924.2958|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250114|-5356937.8395|-5108954.4358|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250115|3833215.3558|3725100.3347|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250116|1.72373915509E7|1.72627253957E7|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250117|7608031.4752|7984222.446|185|
|AXSM|AXSM.O|Axsome Therapeutics|20250121|1832802.8263|2106307.2579|185|

5. **Market Sentiment and Outlook**:
- The company's technical patterns include a "Bullish Engulfing" and "Spinning Top White," which are generally positive signals.
- Axsome Therapeutics has been rated as a "Strong Buy" by analysts, with an average 1-year target price of $175.33, indicating a potential upside of 75.59%.

In conclusion, AXSM's technical indicators, analyst ratings, and pipeline advancements suggest a positive outlook for the stock. Investors should monitor the company's continued progress in developing its pipeline and addressing regulatory challenges.